arrow
L

Livia Lamartina

Centre Hospitalier Universitaire d'Angers
H指数:36
被引数:5,517

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas

法国ENDOCAN-COMETE网络对罕见肾上腺皮质癌总生存期的影响

2026-05-010
PRE
Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine

病灶剂量测定在131I难治性转移性分化型甲状腺癌中的应用,该患者携带BRAFp.V600E或RAS突变,并接受trametinib(±dabrafenib)治疗,随后进行放射性碘治疗

2026-03-190
PRE
ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer

ENDOCAN TUTHYREF网络共识建议:难治性滤泡性甲状腺癌

2025-05-070
PRE
Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasms

不同器官来源的神经内分泌肿瘤G3中p53和Rb状态的诊断相关性: 465高级别神经内分泌肿瘤的免疫组织化学研究

2024-12-130
PRE
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
LANCET
IF88.5
2024-03-0115
PRE
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study

一项国际多中心研究中甲状腺髓样癌基因组谱与肿瘤特征和临床结局的关系

THYROID
IF6.7
2024-02-0119
OA
Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma

预测甲状腺髓样癌无复发生存率的新型预后列线图

2024-01-224
OAAI
Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports

烷化剂诱导的甲状腺髓样癌的高肿瘤突变负荷和对免疫检查点抑制剂的反应: 两例病例报告

THYROID
IF6.7
2023-11-011
PRE
EO2401 (E) peptide immunotherapy plus nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
2023-10-011
OA
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network
THYROID
IF6.7
2023-10-018
PRE